← Live StudiesRegistry: recruitingPhase 3

Enicepatide for obesity with type 2 diabetes

Compares once-weekly investigational enicepatide, at several doses, with placebo for weight management in adults with obesity or overweight and type 2 diabetes.

Ask about this study Refer a patient View official study record

Who it's for

Age 18+
BMI ≥27
Type 2 diabetes with specified HbA1c and stable treatment

Full eligibility rules apply. The study team decides who can take part.

Where it runs

8 research locations in Arizona and California.

Arizona

Arizona Clinical TrialsTucson, AZ

California

University of California IrvineIrvine, CA
Orange County Research CenterLake Forest, CA
Ark Clinical ResearchLong Beach, CA
Catalina Research Institute, LLCMontclair, CA
Infinity Clinical ResearchNorco, CA
Prospective Research Innovations Inc.Rancho Cucamonga, CA
Encompass Clinical ResearchSpring Valley, CA

Site recruitment may change. The official record lists every location, including outside these states.

Interested in this study?

Ask us about it, or refer a patient. Taking part is voluntary, and the study team decides who can join.

Ask about this study Refer a patient

Important information about clinical research

InvestigatorX is an independent information directory. Being listed here does not mean a sponsor, research institution or investigator is affiliated with InvestigatorX. ClinicalTrials.gov registration is not FDA approval of a study drug, an endorsement, or confirmation that a particular site is currently accepting participants.

Summaries are informational and do not determine clinical eligibility. Research can involve risks, including investigational medications and placebo assignment. Always review the ClinicalTrials.gov study basics and speak with a qualified healthcare professional and the authorized study team.

No medical information is collected on this page. For accurate criteria, contacts, and the latest recruitment status, select View official study record on each study's page.

Research listings compiled October 20, 2026. Source: U.S. ClinicalTrials.gov and registry-indexed study information. Independent site; not a U.S. government service. Study data can change without notice.